CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 7th Annual Evercore ISI HealthCONx Conference. Management is scheduled to participate in a fireside chat discussion on December 5, 2024, at 8:20 am ET. Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at htt ...

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference  Presentation Date:December 4, 2024  Time:7:55 ...

Core Insights - Mapi Pharma Ltd. is participating in the 7th Annual Evercore HealthCONx Conference from December 3-5, 2024, in Coral Gables, Florida, to explore partnership opportunities for its innovative long-acting depot injectable treatments [1][2]. Company Overview - Mapi Pharma is a fully integrated, late-stage clinical development biopharmaceutical company focused on developing Lifecycle Management products using extended-release Depot technologies across various therapeutic areas, including multiple sclerosis (MS), diabetes, and schizophrenia [3][6]. - The company has a strong intellectual property (IP) portfolio and is engaged in the development of high barrier-to-entry and high added-value life cycle management products [6]. Development and Manufacturing Capabilities - Mapi Pharma has a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply, allowing for efficient integration of R&D, clinical studies, registration, and manufacturing [4]. - The company has a dedicated R&D team and Depot labs, which enhance its capabilities in developing Depot products [4]. Partnership Opportunities - Mapi Pharma is actively seeking partnerships for its proprietary Depot products, including Deutetrabenazine (AUSTEDO® XR) Depot for Huntington's disease and Anastrazole (Arimidex®) Depot for hormone receptor-positive early breast cancer [5]. - The company offers to conduct formulation development, preclinical studies, and manage clinical development for partners, who will finance development costs and handle commercialization [5]. Product Pipeline - Mapi's lead product, GA Depot, is partnered with Viatris for the treatment of Relapsing Forms of Multiple Sclerosis (RMS) and is currently under FDA review following successful Phase 3 results [6]. - The company is also developing Depot drugs for various conditions, including schizophrenia, diabetes, weight control, Parkinson's disease, and potentially Alzheimer's [6].

Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's disease, Parkinson's disease, schizophrenia, and other CNS diseases [3] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3] - ANAVEX®2-73 targets SIGMAR1 and muscarinic receptors, aiming to restore cellular homeostasis and has demonstrated various beneficial properties in preclinical studies [3] Upcoming Events - Christopher U. Missling, PhD, President and CEO of Anavex, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024 [1] - The conference will feature over 600 industry experts and corporate leaders from more than 225 healthcare companies, covering major healthcare verticals [2] Research and Development - Anavex has received a research grant from The Michael J. Fox Foundation for Parkinson's Research to support the development of ANAVEX®2-73 for Parkinson's disease [3] - Another drug candidate, ANAVEX®3-71, is in clinical stages and shows promise in addressing Alzheimer's disease hallmarks in preclinical trials [3]

NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media ...

Core Insights - Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies [3] - The company will have its President and CEO, Steven Kelly, participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 5th at 9:35 am ET [1] - An audio webcast of the event will be available on the company's Investor Relations webpage and archived for a limited time [2] Company Overview - Carisma Therapeutics utilizes a proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies for cancer and other serious diseases [3] - The company is headquartered in Philadelphia, PA [3] - For more information, the company’s website is www.carismatx.com [3]

LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours afte ...

Core Viewpoint - Evercore's recent earnings report shows strong performance with adjusted earnings per share surpassing estimates, driven by revenue growth in key segments, although rising expenses present a challenge [2][3][5]. Financial Performance - Adjusted earnings per share for Q3 2024 were $2.04, exceeding the Zacks Consensus Estimate of $1.95 and up from $1.30 in the prior year [2]. - Total revenues reached $738.4 million, beating the consensus estimate of $695.4 million, and reflecting a year-over-year increase of 28.6% [4]. - Adjusted net revenues were $739.5 million, up 28.4% year over year, while total expenses rose 24.1% to $612.2 million [5]. Segment Performance - Investment Banking & Equities segment saw net revenues increase by 29% year over year to $712.8 million, with operating income surging 59% to $116.4 million [8]. - Investment Management segment reported net revenues of $21.4 million, a 22% increase from the prior year, with operating income up 55.1% to $5.6 million [8]. Asset Management - Assets Under Management (AUM) stood at $13.9 billion as of September 30, 2024, marking a 23.2% increase year over year [9]. Balance Sheet - As of September 30, 2024, cash and cash equivalents were $533.1 million, with investment securities and certificates of deposit totaling $1.3 billion. Current assets exceeded current liabilities by $1.6 billion [10]. Capital Distribution - In the reported quarter, Evercore repurchased 0.4 million shares at an average price of $236.91 [11]. Market Outlook - Estimates for Evercore have trended downward recently, with a consensus estimate shift of -5.58% [12][13]. The stock currently holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [15]. Industry Comparison - Evercore operates within the Zacks Financial - Investment Bank industry, where competitor Goldman Sachs reported revenues of $12.7 billion, a year-over-year increase of 7.5% [16].

WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will pa ...

FRANKLIN LAKES, N.J., Nov. 19, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 10:50 am Eastern Time.The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.About BDBD is one of the ...